Levosimendan Reig Jofre

Levosimendan, the active ingredient in Levosimendan Reig Jofre, is a calcium sensitizer / inotropic agent presented as an intravenous solution for intravenous use. It treats acute decompensated heart failure and may be used in cardiogenic shock under specialist supervision.

GNH USA supplies Levosimendan Reig Jofre as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan is used in the management of acute heart failure and related circulatory emergencies.

Acute decompensated heart failure: improves cardiac output and relieves pulmonary congestion. Cardiogenic shock (off‑label): provides inotropic support when conventional therapy is insufficient. Severe left ventricular dysfunction: enhances myocardial contractility to stabilize hemodynamics.

Levosimendan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Hypotension: transient drop in blood pressure. - Nausea or vomiting: gastrointestinal discomfort. - Tachycardia: increased heart rate. - Dizziness: sensation of light‑headedness. - Arrhythmias: occasional premature beats.

Serious or Rare Side Effects: - Severe hypotension: may require vasopressor support. - Life‑threatening arrhythmias: ventricular tachycardia or fibrillation. - Myocardial ischemia: chest pain or ECG changes. - Anaphylactic reactions: rash, swelling, respiratory distress. - Hepatic enzyme elevation: significant increase in transaminases. - Thrombocytopenia: marked reduction in platelet count.

Levosimendan requires careful clinical monitoring and consideration of patient‑specific factors.

Hemodynamic monitoring: continuous blood pressure and cardiac output assessment is essential. Renal impairment: dose adjustment may be needed in severe renal dysfunction. Hepatic dysfunction: use with caution; monitor liver enzymes. Concomitant vasodilators: increased risk of additive hypotension. Pregnancy: safety not established; avoid unless benefit outweighs risk. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Potent vasodilators (e.g., nitroprusside): may cause profound hypotension. - Strong CYP450 inhibitors (e.g., ketoconazole): can raise plasma concentrations. - Other inotropes (e.g., dobutamine) without monitoring: risk of excessive cardiac stimulation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the desired inotropic effect. - Diuretics: can enhance hypotensive response. - Anticoagulants: monitor for bleeding if severe hypotension occurs.